BioLineRx Altman Z-Score
The Altman Z-Score of BioLineRx (BLRX) as of Oct 18, 2026 is -13.33. In the previous year, Altman Z-Score was -13.45 — a change of -0.89% (higher).
Get this data via API
Financial Data API
Altman Z-Score
-13.33
YoY
-0.89%
Last updated:
The BioLineRx Altman Z-Score history
3 Years
10 Years
25 Years
Max
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| -13.33 | -0.89% | |
| -13.45 | +18.82% | |
| -11.32 | +62.81% | |
| -6.95 | +23.69% | |
| -5.62 | -43.00% | |
| -9.86 | +27.04% | |
| -7.76 | +20.67% | |
| -6.43 | +33.36% | |
| -4.82 | -10.23% | |
| -5.37 | +83.60% | |
| -2.93 | -42.82% | |
| -5.12 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioLineRx Stock analysis
Frequently Asked Questions about BioLineRx stock
Altman Z-Score of BioLineRx is -13.33 in 2025.
On Eulerpool you can find the complete historical development of Altman Z-Score BioLineRx since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — BioLineRx
All Key Metrics — BioLineRx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth